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Abstract
Background: In advanced stages of Parkinson’s disease (PD), patients and neurologists regularly face complex
treatment decisions. Shared decision-making (SDM) can support the process where evidence, the clinician’s
expertise and the patient’s preferences jointly contribute to reach an optimal decision. Here, we describe the
rationale of our feasibility study protocol.
The aim of the study is to test the feasibility of the SDM intervention by (1) analysing the acceptability of the intervention
by users (i.e. professionals and patients), (2) assessing the level of implementation, (3) testing efficacy on a small scale and
(4) evaluating the study procedures.
Methods: Using an uncontrolled before-after mixed methods design, patients in the pre-intervention group will receive
information and decisional support as usual. Patients in the post-intervention group will receive the SDM intervention,
consisting of an Option Grid™ patient decision aid and a website with supplementary information plus a
value clarification tool for both patients and professionals. An Option Grid is a one-page, evidence-based
summary of available options, listing the frequently asked questions that patients consider when making
treatment decisions. A value clarification tool helps patients identify which option he/she prefers based on
attributes in the treatment decision context. Neurologists and PD nurse specialists will receive a 1-h
instruction on SDM and how to use the SDM intervention.
Through purposive sampling, neurologists and PD nurse specialists will be recruited from both specialised
neurology clinics and community-based hospitals. Included professionals will invite consecutive patients who
are eligible for the advanced therapies.
Data will be collected using questionnaires, interviews and audio observations of the consultations and by
tracking users’ logging behaviour of the website. Data will be analysed using a mixed methods design.
Discussion: The mixed methods design will create a deeper understanding of how the SDM intervention
affects the interactions between professionals (a neurologist and/or a PD nurse specialist) and the patient,
when an advanced treatment is chosen. The results of the study will inform the design of an RCT to test
the effectiveness of the SDM intervention.
Trial registration: NTR6649, retrospectively registered 28 August 2017.
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Background
In the advanced stage of Parkinson’s disease (PD), disability
accumulates significantly due to a range of motor and non-
motor complications. Of these, motor fluctuations have a
major impact on quality of life and it has been shown that
advanced treatments (deep brain stimulation (DBS),
levodopa-carbidopa intestinal gel (LCIG) or continuous
subcutaneous apomorphine infusion (CSAI)) improve
motor function and may thus convey substantial benefit.
However, neurologists and PD patients face a complex de-
cision choosing between available treatment options and
selecting the one that best suits the patient’s needs. For
various reasons, the application of the evidence-based
medicine principles to this particular decision is challenging
[1]. Randomised controlled trials comparing all three ad-
vanced treatments are lacking [2], and many professionals
fail in bridging this knowledge gap due to a lack of treat-
ment experience or availability at their site [3]. Conse-
quently, a large proportion of PD patients are not fully
informed on all advanced treatment options by their neu-
rologists [3–5]. And more importantly, PD patients feel in-
sufficiently involved in the decision-making process [3, 6].
To overcome the aforementioned limitations in the
decision-making process, shared decision-making (SDM)
can play a pivotal role [7]. SDM represents the process
of decision-making in which the professional and pa-
tient, and possible other key players, define the decision
to be made, share the treatment options and available
evidence, elicit the patient’s preferences and reach a
shared decision [8–10]. SDM can be facilitated by a de-
cision aid [10]. A decision aid states the decision to be
made on a health problem, provides the available evi-
dence on the options, including the scientific uncertain-
ties, and supports patients in clarifying what values are
important to them personally. A decision aid thus sup-
ports the patients and professionals to actively partici-
pate in decision-making [11].
In this paper, we describe the design of a feasibility
study examining the SDM intervention in the
decision-making process for an advanced therapy in
PD. The intervention we designed consists of an Op-
tion Grid ™ patient decision aid, online supplementary
information with a value clarification tool and a 1-h
training for professionals on SDM and how to use
the SDM intervention. An Option Grid is a one-page,
evidence-based summary of available options pre-
sented in a tabulated format, listing the frequently
asked questions that patients consider when making
treatment decisions [12]. An Option Grid is used in
the clinical encounter and stimulates the discussion
about the treatment options [13]. A value clarification
tool helps a patient to think about which attributes of
options matter to him/her most, to identify which op-
tion fits best his/her personal life [14].
The study will address the feasibility of the SDM inter-
vention by (1) analysing the acceptability of the interven-
tion by users (i.e. professionals and patients), (2)
assessing the level of implementation, (3) testing efficacy
on a small scale and (4) evaluating the study procedures.
Methods
Study design
This feasibility study has a multi-centre, uncontrolled
before-after, mixed methods design, with five participating
centres. A before-after design creates the possibility for pro-
fessionals to reflect on their practice pre- and post-
intervention. The rationale for a feasibility study is to first
examine if the intervention will be accepted by its users
and can be implemented in clinical practice before we can
test effectiveness [15]. The ideal sample size for a feasibility
study ranges between 24 and 50 patients for the total sam-
ple size [16, 17]. We aim for a total of 40 patients at this
stage: 20 in the pre-intervention group (baseline group)
and 20 in the post-intervention group. Based on our previ-
ous study [4], we estimate that the majority of professionals
in community-based hospitals consider three to ten pa-
tients for an advanced therapy per year. Because the SDM
intervention is a complex intervention, using a mixed
methods design will achieve cross-validation or triangula-
tion of the data. With the triangulation, we aim to gain a
more complete understanding of the effects of the SDM
intervention [18]. To increase the understanding, we will
also measure contextual factors, such as cognitive deficits
in patients and treatment expertise of professionals that can
influence the outcome measures.
Participants
Hospitals
Five hospitals in the Netherlands will participate and were se-
lected from our previous studies [3, 4]. Specialised neurology
centres and community-based hospitals will be represented,
with variable accessibility to advanced PD treatments.
Professionals
Neurologists will be eligible if they (1) consider at least
five PD patients per year for advanced treatment and (2)
collaborate with a PD nurse specialist in the same hospital.
We aim for a total of five to ten neurologists. A participat-
ing hospital can provide more than one neurologist.
Moreover, we aim to include professionals with different
levels of expertise on the advanced treatment options.
Patients
Patients are included in a convenient consecutive sample
and can be included if they (1) are diagnosed with ad-
vanced PD and are considered to be a suitable candidate
for advanced treatment, judged by their own neurologist
and (2) are eligible for all three treatments at the
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beginning of the decision-making process. Patients who
currently have or previously underwent an advanced
treatment for PD are excluded.
The intervention
The intervention has been developed following the process
map for web-based decision support interventions [19].
The SDM intervention consists of an Option Grid patient
decision aid and a website with supplementary information
plus a value clarification tool, and a 1-h training for profes-
sionals. The key element of the SDM intervention is the
Option Grid, and it will be used in the first encounter to
start the discussion on the treatment options. Patients will
then be referred to the website for more elaborate informa-
tion. The online supplementary information is divided into
a patient-dedicated site and a professional-dedicated site.
The patient site provides a short instruction video about
the website, more detailed information on the decision to
be made, the Option Grid itself, detailed information on
the treatment options and the value clarification tool. The
professional site presents the Option Grid, a template for
the decision process and the evidence synthesis on which
the Option Grid is based. Both sites are transparently ac-
cessible for both patients and professionals.
The main researcher (FN) provides an on-site 1-h inter-
active training to the participating neurologists and PD
nurse specialists. During the training, the concept of SDM
and the deliberative consultation model will be introduced
[8]. Furthermore, the use of the Option Grid patient deci-
sion aid and the online supplementary information will be
explained. The training will not be extensive as we want
to analyse how professionals use the SDM intervention in
real-life situations, without any prescribed behaviour, as
the Option Grid patient decision aid will be publicly avail-
able without training after the study [12].
Study procedures
Consecutive patients, found to be eligible for an ad-
vanced treatment by the neurologist, will be invited to
participate in the study. The patients will receive written
information from their neurologist or PD nurse special-
ist, before written informed consent is obtained.
In the pre-intervention group, patients will receive in-
formation and decision support as usual. The decision
process of an individual patient ends when a preliminary
choice for a treatment has been made and the screening
for definite treatment eligibility is initiated.
Once 20 patients in the pre-intervention group have
finished their decision process, the professionals will
participate in the 1-h training. Next, the 20 patients of
the post-intervention group will be included and enter
the decision process making use of the Option Grid pa-
tient decision aid and website. Every neurologist and PD
nurse specialist will receive a personal login code after
the training for the website. Once patients in the post-
intervention group are included and have been intro-
duced to the Option Grid by the professional, they will
receive their unique login code as well.
Outcome measures
This feasibility study will focus on four aspects, being
acceptability, level of implementation, small-scale effi-
cacy testing and evaluation of study procedures, each
with their own relevant outcome measures (Table 1).
In order to increase cross-validation of the data con-
textual factors will also be measured (Table 1).
Acceptability of the SDM intervention
Acceptability evaluates how the neurologists, PD nurse spe-
cialists and patients react to the intervention [20]. Assess-
ment of acceptability is paramount as it predicts whether
the intervention will be adopted and used. Acceptability will
be evaluated based on a manual for testing acceptability of a
decision aid [21]. Acceptability is tested by questions on
readability, comprehensiveness, layout, amount of informa-
tion as well as the professional’s and patient’s opinions about
the SDM intervention and suggestions for improvement.
Level of implementation of the SDM intervention
Implementation evaluates whether the SDM interven-
tion is executed as planned. The level of implementa-
tion will be evaluated in terms of the changes made
to the SDM intervention while using it, the perceived
level of implementation of the SDM intervention, and
the experienced barriers and facilitators in using the
intervention. Moreover, the utilisation of the different
elements of the SDM intervention will be measured.
Small-scale efficacy testing of the SDM intervention
The aim of the intervention is to improve SDM and the
quality of the decision in advanced PD. Testing the feasi-
bility of the intervention also includes a small-scale effi-
cacy testing to guide the choice of outcome measures for
the future RCT [21]. We will focus on two efficacy out-
come domains. First, the elements within the SDM
process that are used during the consultations (‘level of
SDM’) are assessed in a triadic approach, meaning that
the level of SDM is evaluated from three perspectives (i.e.
patient, professional, observer). It includes four validated
measurement instruments, i.e. OPTION-5 [22] (observa-
tional measurement), CollaboRATE [23], SDMQ9-patient
(patient-reported outcome measures) and SDMQ9-doc
(professional-reported outcome measure) [24].
Secondly, we assess the quality of decision-making. A
decision is considered of high quality if it is based on
sufficient knowledge and is in alignment with one’s per-
sonal preferences [25]. To capture this, we have selected
three instruments, i.e. the level of informed choice
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(knowledge test), the Decisional Conflict Scale (DCS)
[26] and the Provider Decision Process Assessment In-
strument (PDPAI) [27, 28].
Feasibility of study procedures
An evaluation of the study procedures is performed
to learn lessons for a future randomised controlled
trial. Inclusion procedures and drop-out rates will be
monitored. The interviews will address the profes-
sional’s and subject’s conflicting responses on out-
come measures, opinions about the study procedures
and suggestions for improvement. Field notes will be
used to evaluate any logistical problems in the study
procedures.
Table 1 Study methods and instruments
Research objectives Components Methods and instruments
Demographic data Demographic data Baseline questionnaire with questions on demographics
Acceptability 1. Satisfaction with intervention and how intervention
is received
1a. Structured questionnaires for patients on items as readability,
comprehensiveness, layout and amount of information
1b. Semi-structured interviews with patients, neurologists and PD
nurse specialists with items on perceived satisfaction, and perceived
strengths and weaknesses of the intervention
Level of
implementation
1. To what extent is the intervention implemented
as planned
2. To what extent were all components of the
intervention used
3. How did participants react to the specific aspects
of the intervention and to what extent did patients
engage in the intervention
4. What proportion of the included population
actually were using the intervention
1. Field notes to what extent the intervention was implemented as
planned and training was provided as planned
2. Analysis of audiotapes consultations, logging data of navigation
behaviour website and hard copies of value elicitation tool summary:
evaluation if all elements of intervention are actually used
3a. Analysis of audiotapes consultations and logging data of navigation
behaviour website to analyse if patients engage in all elements of the
intervention
3b. Semi-structured interviews on the perceived interaction with the
different elements of the intervention
4. Analysis of audiotapes consultations and logging data of navigation
behaviour website to analyse which patients in the intervention group
and professionals were using the intervention during the decision
process
Small-scale
efficacy testing:
- Level of SDM
1. Patient and neurologist/PD nurse perceived
level of SDM
2. Researcher observed level of SDM
1. Structured questionnaires for patients and neurologists/PD nurse
specialists using the following validated scales: SDMQ-9 (patients) and
SDMQ-9-doc (neurologists/PD nurse specialists), CollaboRATE (patients)
and CPS actual role (patients, neurologists, PD nurse specialists)
2. Analysis of the audiotaped consultations using the validated scale:
OPTION-5
Small-scale efficacy
testing:- Decision
quality
1. Level of informed choice
2. Decisional conflict in decision-making
1. Measuring knowledge in patients at the start and end of decision-
making process using questionnaire with 20 questions on the advanced
treatments
2. Structured questionnaires for patients and neurologists/PD nurse
specialists using the following validated scales: DCS (patients) and
PDPAI (neurologists/PD nurse specialists)
Feasibility of
study procedures
1. Recruitment
2. Potential outcome indicators
3. Approaches to data collection
1a. Field notes on study inclusion rate, drop-out rates
1b. Semi-structured interviews with neurologists and PD nurse specialists
with items such as barriers to recruitment
2. Analysis of outcome measures from the small-scale efficacy testing
with evaluation of conflicting data on outcome measures
3. Semi-structured interviews with patients and neurologists/PD nurse
specialists with items on acceptability of the logistics/practicability of
the study procedures
Context 1. Patient-related factors in the implementation and
outcomes
2. Professional-related factors in the implementation
and outcomes
3. Organisational context
1a. Structured questionnaires for patients with items on preferred role in
decision-making (CPS), treatment preference, pre-knowledge, health
literacy skills (FCHHL) and mood (HADS)
1b. Cognitive testing using MoCA, BSAT, Verbal Fluency, Stroop Color
Word Test, National Adult Reading Test, Raven Advanced Progressive
Matrices and MMSE
2. Structured questionnaires for neurologists and PD nurse specialists
with items on their role in decision-making (CPS), treatment preference
and level of experience with treatments
3. Field notes on national consensus of treatment of advanced PD,
organisational structure for this specific decision in participating centres
CPS control Preference Scale, FCCHL Functional Communicative and Critical Health Literacy, HADS Hospital Anxiety and Depression Scale, MoCA Montreal Cognitive
Assessment, BSAT Brixton Spatial Anticipation Test Provider Decision Process Assessment Instrument, MMSE Mini Mental State Examination, PDPAI Provider
Decision Process Assessment Instrument
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Context
In order to correctly interpret the results on the above-
mentioned outcomes, it is imperative to know which ex-
ternal factors influence the acceptability, implementation
and outcomes [29–31]. We have defined a limited set of
contextual factors, based on our previous findings [3].
They include (1) cognitive deficits in PD patients that
could limit the use of the SDM intervention, (2) treat-
ment preference of patients at forehand that could influ-
ence which components of the SDM intervention are
used, (3) level of experience with the treatments of the
professionals that could influence how they introduce
the SDM intervention to the patients and (4) organisa-
tional factors such as changing consensus nationally on
advanced treatments.
Data collection
Cognitive testing
The main researcher (FN) will visit the patient at his/her
home to conduct the cognitive test battery. The esti-
mated time to complete the cognitive test battery is
around 45 min. The researcher will try to conduct the
test at a moment after the patient has taken medication
to ensure optimal testing conditions. However, patients
in this stage of the disease can have unpredictable fluc-
tuations in functioning during the day. The test battery
will be conducted in the same order in each patient to
eliminate changes between different tests due to fatigue
or loss of concentration.
Questionnaires
Professionals will complete a baseline questionnaire at the
start of the study to collect demographic information and
an exit questionnaire to collect their experiences with the
SDM intervention at the end of the study. They will also
complete two short digital questionnaires per patient: one
at the start and one at the end of the decision-making
process. The two short questionnaires will contain the
outcome measures for small-scale efficacy testing.
Patients will complete a baseline questionnaire to collect
demographic information immediately after inclusion.
After the first consultation when the options have been
discussed, patients will be invited to complete a question-
naire which contains questions about contextual factors
that could interact with the decision-making process and
some of the outcome measures for the efficacy testing.
The next questionnaire will be sent immediately after a
decision for a treatment has taken place, and this ques-
tionnaire will address outcome measures for efficacy test-
ing. Finally, patients will receive an exit questionnaire to
collect feedback on the decision process. In the post-
intervention group, this questionnaire also addresses the
SDM intervention.
Observations
We aim to audiotape all consultations covering the
decision-making process, i.e. two to three per patient. It
may prove difficult to record the first consultation when
the professional introduces the option to change treat-
ment, as this can occur before informed consent has
been obtained. Consent for the audiotapes will be in-
cluded explicitly in the consent form.
Interviews
Interviews with professionals will be conducted at the end
of the study. The interviews will cover in-depth analysis
on the acceptability of the intervention, how the interven-
tion was used and barriers and facilitators for the integra-
tion into the work process, suggestions for improvement,
as well as feasibility of the study procedures.
Interviews will be conducted with all patients at the
end of their decision-making process. The interviews
will elaborate on the decision process and feasibility of
study procedures. Patients in the post-intervention
group will also be asked how the SDM intervention was
used in the decision process, the acceptability of the
intervention, barriers and facilitators to implementation
and suggestions for improvement.
Tracking navigation behaviour of the website
Tracking the online navigation behaviour will only be
applied in the post-intervention part of the study proto-
col. The quantitative measures of utilisation of the SDM
intervention website will be obtained through tracking
analysis software, capturing both time-dependent (dur-
ation of website and component use) and navigation-
dependent (navigational route, navigational step count,
print commands, use of dedicated sites) variables. Pa-
tients will be asked to hand in the printed summary of
the value clarification exercise as a source of information
to see if patients use the value clarification tool.
Field notes
Field notes by the researcher are used to evaluate any diffi-
culties observed in the study procedures, such as inclusion
rate, difficulties using the SDM intervention, and prob-
lems filling in the questionnaires. It is possible that the
SDM intervention has to be adapted during the study. Ad-
aptations can be necessary to make the intervention fit
into different contexts. These adaptations will be reported
in field notes, taken by the researchers throughout the
study period. External factors that can influence the out-
come measures and are observed during the study period
will also be written down by the researcher in the field
notes. An example is for instance if the national consensus
changes on what appropriate advanced treatment options
are, which would change the options that have to be in-
cluded in the Option Grid and website (Table 2).
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Sample size calculation
As this is a feasibility study, we have not performed a sam-
ple size calculation [32]. The rationale for the sample size
of 20 pre- and 20 post-intervention group participants has
been given above in the study design section.
Data analysis
For multidimensional understanding of the “black box of
decision-making” and increasing validity of the data, we
will create a mixed methods matrix combining the quan-
titative and qualitative data and use a triangulation
protocol [33, 34].
Quantitative analysis
Descriptive statistical analysis will be conducted on socio-
demographic characteristics of patients and professionals.
To assess the feasibility of this study, descriptive analyses
will be conducted on: inclusion rate (number of participant
inclusions per quarter), retention rate (number of partici-
pants completing full study procedures), intervention im-
plementation rate (number of participants in post-
intervention group using intervention) and missing data
(proportion fully completed per scale/questionnaire). Quan-
titative data will be reported as percentages, numeric
counts, mean ± standard deviation (SD) or median and
interquartile range (IQR), as appropriate. Differences be-
tween the pre- and post-intervention values will be tested
parametrically or non-parametrically, depending on the
outcomes being normally or not normally distributed. A p
value less than 0.05 will be considered statistically signifi-
cant. All results will be presented with 95% confidence in-
tervals. Any hypothesis testing will be treated as
preliminary and the results interpreted with caution as the
study is likely to be underpowered to detect statistically sig-
nificant differences. Unintended or unexpected effects will
be documented. Results of any other analyses performed,
which could be used to inform the future definitive RCT,
will be explicitly described [35]. All analyses will be con-
ducted using SPSS (Statistical Package for Social Sciences,
Chicago, IL, USA).
Qualitative analysis
Audio-recordings of the consultations and the interviews
will be transcribed verbatim. We will qualitatively analyse
all consultations and interviews using thematic analysis
[36]. Themes or patterns within data can be identified in
an inductive or ‘bottom up’ manner, or in a theoretical or
deductive, ‘top down’ manner [36]. As the analysis will be
based on our previous work [3] and other literature, the
theoretical analysis is more appropriate. Thematic analysis
will consist of a cycle of several steps. In the initial phase,
two researchers will familiarise themselves with the data by
reading through all transcripts several times and generate
initial codes. A code is any interesting feature, which relates
to the main research question, mentioned by the partici-
pants (patients and/or professionals) in the interviews or an
outstanding observation from the consultations. We will
cluster the codes into categories, when they describe or
Table 2 Data collection scheme
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relate to the same phenomena. In the next phase, codes
can be reassigned or renamed, after which themes are de-
veloped. Next, the categories and themes will be discussed
with the research team and codes and categories will be
reevaluated. The final step is to interpret the data and reach
consensus on the categories and main themes [36]. Atlas-ti
will be used to support the qualitative analysis. We will fol-
low the recommendations outlined in the COREQ criteria
as much as possible to report the qualitative data [37].
Mixed methods analysis
The aim of the triangulation is to explore how the SDM
intervention actually influences the decision process, cre-
ating a multidimensional understanding [38]. Exploring
the mechanisms of impact through which the SDM inter-
vention works helps in understanding the outcome results
and can help identify which adaptations to the interven-
tion are necessary to change unwanted effects. The mech-
anisms of impact will be analysed using triangulation [31].
We will apply two types of triangulation: data triangula-
tion and methodological triangulation. The data triangula-
tion means that data from neurologists, PD nurse
specialists and patients will be used. The methodological
triangulation is represented by different methods of data
collection, using questionnaires, observations, interviews
and field notes and by tracking logging behaviour. For the
analyses, we will first sort the data and then apply a con-
vergence coding scheme, analyse the level of agreement or
dissonance by convergence assessment and evaluate com-
plementarity and divergence. Complementarity analyses
explore whether different findings together explain a
phenomenon or outcome and divergence reflects a dis-
agreement between results from different sources. Each of
these contributes to enhance the validity of the research
findings [34]. After analysing all data, results will be pre-
sented to the research group (all authors). Based on a
group discussion, the researchers will work towards an
agreement on the findings and their interpretation [33].
Discussion
The study will address the following questions: (1) is the
intervention accepted in its current state for implemen-
tation, (2) can the intervention be delivered as intended
and (3) what are the most useful outcome measures to
evaluate the impact of the intervention in a RCT? Pos-
sible problems that we anticipate on are the following:
 Difficulty with inclusion rate: As mentioned before,
each neurologist has a limited number of patients
eligible for these advanced treatments. The patient
has to be eligible for all three treatments, and this
could reduce the actual number of eligible patients
per professional, which could limit inclusion rate.
 Difficulty with obtaining all outcome measures: As
this specific decision-making process is complex and
involves multiple consultations with the patient, neur-
ologist and PD nurse specialist. This increases the risk
of missing data, especially of the audiotapes. We will
try to limit this risk by providing both the individual
patient and the professionals with a voice recorder.
However, we cannot prevent that the professional has
already explained a bit on the three options before the
patient is included, and therefore, a part of the
decision-making process is missing on the audiotapes.
 As it is a convenient consecutive sample of patients,
differences in baseline demographics can influence
the outcome measures.
 Professionals included in the study know we will
introduce a SDM intervention that should improve
SDM. They are asked to give care as usual in the pre-
intervention group; however, it could be that they will
change their behaviour because they are evaluated.
The results of this project will evaluate the feasibility of
the SDM intervention with all these constraints taken into
consideration and will inform the design of a RCT in clin-
ical practice to evaluate the intervention on effectiveness.
Our long-term goal is to offer patients the opportunity to
actively participate in the self-management of their disease,
including involvement in complex medical decision-
making.
Trial status
Patient inclusion started in May 2015. In April 2018,
75% of the total inclusion was completed and inclusion
is ongoing.
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